MDS classification is improving in an era of the WHO 2016 criteria of MDS: A population-based analysis among 9159 MDS patients diagnosed in the Netherlands

Conclusion The classification of MDS is improving in the Netherlands. Nevertheless, particular diagnostic and prognostic procedures that are essential for the diagnosis and subsequent treatment decision-making of MDS were not fully utilized in particular patient subsets.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research

Related Links:

ConclusionAccording to the criteria for bioequivalence, the test formulation of lenalidomide and Revlimid® was determined to be bioequivalent.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Efforts to Focus on Pre-Clinical and Clinical Research for up to 16 Early-Stage Programs Across Various Types of Cancer Multi-Year Agreements Build on Long-Term Partnership in Immuno-Oncology, Including BiTE® Therapies and now CAR T Programs THOUSAND OAKS, Calif. and HOUSTON, May 31, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and The University of Texas MD Anderson Cancer Center today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen's early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung ...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Amgen today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen's early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung cancer, and other non-lung cancers with small-cell histologies.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Myelodysplastic syndromes current treatment algorithm 2018, Published online: 24 May 2018; doi:10.1038/s41408-018-0085-4Myelodysplastic syndromes current treatment algorithm 2018
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
ker Higher-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) of the elderly exhibit several commonalities, including first line treatment with hypomethylating agents (HMA) like azacitidine (AZA) or decitabine (DAC). Until today, response to treatment occurs in less than 50 percent of patients, and is often short-lived. Moreover, patients failing HMA have a dismal prognosis. Current developments include combinations of HMA with novel drugs targeting epigenetic or immunomodulatory pathways. Other efforts focus on the prevention of resistance to HMA using checkpoint inhibitors to enhance immune attack. ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
(Mayo Clinic) In a recent study published in the Journal of Clinical Investigation, Mayo Clinic researchers identified that an FDA drug approved for myelodysplastic syndrome may be useful to treat triple-negative breast cancer, which is one of the most aggressive and lethal types of breast cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Luteolin induces myelodysplastic syndrome‑derived cell apoptosis via the p53‑dependent mitochondrial signaling pathway mediated by reactive oxygen species. Int J Mol Med. 2018 May 18;: Authors: Dong W, Lin Y, Cao Y, Liu Y, Xie X, Gu W Abstract Luteolin, a common dietary flavonoid, induces the apoptosis of cells in several types of cancer. However, its role in myelodysplastic syndrome (MDS) and the potential underlying mechanisms remain to be elucidated. To evaluate the potential benefit and underlying mechanisms of luteolin in MDS cells, the viability of SKM‑1 cells and primary bone marrow (PBM)...
Source: International Journal of Molecular Medicine - Category: Molecular Biology Authors: Tags: Int J Mol Med Source Type: research
In this study, we investigated 500 cases referred to Legacy Laboratory Services since 2007 for clinical features related to MDS.
Source: Cancer Genetics and Cytogenetics - Category: Genetics & Stem Cells Authors: Source Type: research
Abstract Isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) are key metabolic enzymes that catalyze the conversion of isocitrate to α-ketoglutarate (αKG). IDH 1 and IDH2 regulate several cellular processes, including oxidative respiration, glutamine metabolism, lipogenesis, and cellular defense against oxidative damage. Mutations in IDH1 and IDH2 have recently been observed in multiple tumor types, including gliomas, acute myeloid leukemia, myelodysplastic syndromes, and chondrosarcoma. IDH1 and IDH2 mutations involve a gain in neomorphic activity that catalyze αKG conversion to (R)-2-hydroxygluta...
Source: Current Topics in Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Top Med Chem Source Type: research
Publication date: August 2018 Source:Cancer Genetics, Volumes 224–225 Author(s): Nisha Mathew, Jacob Smith, Emma Weirich, Donna Blackwell, Yassmine Akkari
Source: Cancer Genetics - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Epidemiology | Myelodysplastic Syndrome | Netherlands Health